Effect of buspirone on prolactin and growth hormone secretion in laboratory rodents and man.

Abstract

Preclinical studies have shown buspirone to have some characteristics of both a dopamine (DA) agonist and antagonist. Neuroendocrine and neurochemical studies were conducted to determine which actions occur in rats and man. Buspirone produced a dose-dependent increase in rat plasma prolactin (PRL) levels and enhanced the increase in plasma PRL levels produced by alpha-methyl-p-tyrosine and gamma-butyrolactone. Buspirone also blocked the inhibitory effect of dopamine on PRL secretion in vitro, which is consistent with the action of a DA antagonist. In a double-blind placebo-controlled study using eight normal male volunteers, buspirone (30, 60, and 90 mg) produced a dose-related increase in PRL levels 60-180 minutes later, and a significant increase in growth hormone in six of the eight volunteers, which could be evidence for a DA agonist effect in the human hypothalamus. The anxiolytic effects of buspirone could be due to either DA agonist or antagonist effects.

Statistics

0200400600'91'94'97'00'03'06'09'12'15
Citations per Year

468 Citations

Semantic Scholar estimates that this publication has 468 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Meltzer1982EffectOB, title={Effect of buspirone on prolactin and growth hormone secretion in laboratory rodents and man.}, author={Herbert Yale Meltzer and Rosanna Fleming}, journal={The Journal of clinical psychiatry}, year={1982}, volume={43 12 Pt 2}, pages={76-9} }